Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Zepbound (Tirzepatide) Dose Adjustments for Black / African Ancestry Patients

By
Published Updated Last reviewed
4 linked public sourcesEditorial, sourcing, and corrections policy

HealthRX.com

Black and African ancestry patients follow the same Zepbound schedule

Print or save as PDF

Key numbers

  • 2.5 mgStarting dose for all adults, including Black and African ancestry patients, with no race-based changeSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 15 mgMaximum weekly dose for all indications, including weight reduction and sleep apneaSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 8%Share of Black or African American participants in the pooled weight-reduction trialsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 22%Chronic kidney disease in non-Hispanic Black adults, versus 13% in non-Hispanic White adultsSource: cdc.gov, as cited Nov 7, 2026

From the public record

FDA label facts for tirzepatide

The FDA label read for tirzepatide (Zepbound, application NDA217806) was last revised on 2026-08-28. It carries a boxed warning headed "WARNING: RISK OF THYROID C-CELL TUMORS". Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.

FDA label facts for tirzepatide: the figures
MeasureValueNote
Label revision date2026-08-28
Label readZepboundNDA217806, brand-name application
Boxed warningYesheading as printed: "WARNING: RISK OF THYROID C-CELL TUMORS"
Pregnancy sectionPresent
Lactation sectionPresent
Pediatric use sectionPresent
Geriatric use sectionPresent

Source: FDA drug label via openFDA, viewable on NIH DailyMed, data as of Nov 11, 2026

How this was calculated

Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.

Scope: One label: the newest prescription label for single-ingredient tirzepatide from an original manufacturer, matched to Zepbound

Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.

Download the data (CSV)

At a glance

  • Starting dose / 2.5 mg once weekly for 4 weeks [1]
  • Titration / 2.5 mg steps after at least 4 weeks on the current dose [1]
  • Weight-reduction maintenance / 5, 10 or 15 mg once weekly [1]
  • OSA maintenance / 10 or 15 mg once weekly [1]
  • Maximum dose / 15 mg once weekly [1]
  • Kidney or liver impairment / no dose adjustment [1]
  • Trial population / 8% Black or African American in the pooled weight-reduction trials [1]
  • Severe GI reactions / 1.7% at 5 mg, 2.5% at 10 mg, 3.1% at 15 mg vs 1% on placebo [1]

What dosing schedule does the Zepbound label set?

The dosing section of the Zepbound label gives one escalation schedule for all adults. Treatment starts at 2.5 mg subcutaneously once weekly for 4 weeks, then goes to 5 mg once weekly, and can be raised in 2.5 mg steps after at least 4 weeks on the current dose [1]. The label says the 2.5 mg dose is for initiation and is not approved as a maintenance dose [1].

The label lists maintenance for weight reduction as 5, 10 or 15 mg once weekly. For obstructive sleep apnea in adults with obesity, it lists 10 or 15 mg once weekly. The maximum is 15 mg once weekly for all indications [1]. If a maintenance dose is not tolerated, the label says to consider a lower maintenance dose [1].

Questions worth asking

Choose the questions you want to keep

What does the label say about kidney and liver function?

The Zepbound label states that no dose adjustment is needed for renal or hepatic impairment [1]. It also warns about acute kidney injury due to volume depletion and says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1].

Chronic kidney disease is more common in non-Hispanic Black adults (22%) than in non-Hispanic White adults (13%) in CDC estimates [2].

What safety information is most relevant during titration?

The label warns about severe gastrointestinal adverse reactions, acute kidney injury from volume depletion, acute gallbladder disease, acute pancreatitis, serious hypersensitivity, hypoglycemia with insulin or sulfonylureas, and pulmonary aspiration during general anesthesia or deep sedation [1]. In the pooled weight-reduction trials, nausea occurred in 25%, 29% and 28% of patients on 5, 10 and 15 mg, respectively, versus 8% on placebo; diarrhea in 19%, 21% and 23% versus 8%; and vomiting in 8%, 11% and 13% versus 2% [1]. Most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. Severe gastrointestinal reactions were reported in 1.7%, 2.5% and 3.1% of patients on 5, 10 and 15 mg versus 1% on placebo [1].

The label reports hypotension in 1.6% of Zepbound-treated patients versus 0.1% on placebo. It occurred in 2.2% of Zepbound-treated patients on concomitant antihypertensive therapy versus 1.2% of those not on antihypertensive therapy [1].

What does the trial population show?

In the pooled weight-reduction trials, the population was 72% White, 12% Asian, 8% Black or African American, and 7% American Indian or Alaska Native; 51% identified as Hispanic or Latino [1].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, how does the Zepbound label handle dosing for Black and African ancestry patients?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Frequently asked questions

Do Black or African ancestry patients need a different Zepbound starting dose?
The label's dosing schedule lists no race-based starting dose. All adults start at 2.5 mg subcutaneously once weekly for 4 weeks, then 5 mg once weekly [1].
What are the Zepbound maintenance doses?
For weight reduction, 5, 10 or 15 mg once weekly. For obstructive sleep apnea, 10 or 15 mg once weekly. The maximum is 15 mg once weekly [1].
Does kidney or liver impairment change Zepbound dosing?
No. The Zepbound label states that no dose adjustment is needed for renal or hepatic impairment [1].
How many Black participants were in the Zepbound weight trials?
In the pooled weight-reduction trials the population was 8% Black or African American, alongside 72% White, 12% Asian and 7% American Indian or Alaska Native [1].
Is 2.5 mg a maintenance dose?
No. The label says the 2.5 mg dose is for treatment initiation and is not approved as a maintenance dose [1]. Maintenance for weight reduction is 5, 10 or 15 mg once weekly [1].

References

Show all 4 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
  2. Chronic Kidney Disease in the United States | Chronic Kidney Disease | CDC.
  3. Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis. 2022;79(2):268-288.e1.
  4. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
Evidence overview for Zepbound (Tirzepatide) Dose Adjustments for Black / African Ancestry Patients